Skip to main content

Advertisement

Table 2 Adjusted Cox multivariate analyses of prognostic factors for the matched cohort

From: Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis

Endpoint Variable P value HR 95% CI
OS Gender (male vs. female) 0.334 0.62 0.24–1.63
Age (≤ 50 vs. > 50 years) 0.175 1.63 0.80–3.30
Pretreatment EBV DNA (< 4000 vs. ≥ 4000 copies/mL) 0.766 1.12 0.54–2.29
T stage (T1–2 vs. T3–4) 0.393 1.54 0.57–4.12
N stage (N0–1 vs. N2–3) 0.022 2.26 1.12–4.53
Clinical stage (II–III vs. IV) 0.134 1.86 0.83–4.18
Concurrent chemotherapy (docetaxel vs. cisplatin) 0.802 0.92 0.46–1.83
DMFS Gender (male vs. female) 0.885 0.95 0.48–1.88
Age (≤ 50 vs. > 50 years) 0.901 0.96 0.52–1.79
Pretreatment EBV DNA (< 4000 vs. ≥ 4000 copies/mL) 0.039 1.85 1.030–3.31
T stage (T1–2 vs. T3–4) 0.600 1.22 0.59–2.51
N stage (N0–1 vs. N2–3) 0.017 2.01 1.14–3.58
Clinical stage (II–III vs. IV) 0.530 1.27 0.61–2.64
Concurrent chemotherapy (docetaxel vs. cisplatin) 0.827 1.07 0.60–1.88
LRFS Gender (male vs. female) 0.146 1.85 0.81–4.21
Age (≤ 50 vs. ≥ 50 years) 0.986 0.99 0.41–2.42
Pretreatment EBV DNA (< 4000 vs. ≥ 4000 copies/mL) 0.852 0.92 0.39–2.17
T stage (T1–2 vs. T3–4) 0.418 1.58 0.52–4.79
N stage (N0–1 vs. N2–3) 0.128 1.86 0.84–4.13
Clinical stage (II–III vs. IV) 0.278 0.65 0.29–1.45
Concurrent chemotherapy (docetaxel vs. cisplatin) 0.288 0.65 0.29–1.45
NRFS Gender (male vs. female) 0.337 0.55 0.16–1.88
Age (≤ 50 vs. > 50 years) 0.146 0.40 0.12–1.38
Pretreatment EBV DNA (< 4000 vs. ≥ 4000 copies/mL) 0.171 1.86 0.77–4.52
T stage (T1–2 vs. T3–4) 0.491 0.72 0.28–1.86
N stage (N0–1 vs. N2–3) 0.334 1.55 0.64–3.77
Clinical stage (II–III vs. IV) 0.783 0.81 0.18–3.71
Concurrent chemotherapy (docetaxel vs. cisplatin) 0.036 0.34 0.12–0.93
  1. OS overall survival, EBV Epstein–Barr virus, DMFS distant metastasis-free survival, LRFS locoregional recurrence-free survival, NRFS nodal recurrence-free survival, HR hazard ratio, CI confidence interval